Clinical Trials Browser

Interventional × adavosertib × Head & Neck × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03028766 2024-09-19

WISTERIA

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT01047007 2023-09-21

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Phase 1 Terminated

11 enrolled 10 charts

GastrointestinalHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms

NCT02585973 2021-06-29

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02508246 2019-03-13

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT02196168 2017-05-03

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Terminated

6 enrolled 9 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Tongue Neoplasms